Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403

被引：5

作者：

Goldberg, S. ^{[1
]}

Redman, M. ^{[2
]}

Lilenbaum, R. ^{[1
]}

Politi, K. ^{[1
]}

Stinchcombe, T. ^{[3
]}

Horn, L. ^{[4
]}

Chen, E. ^{[5
]}

Mashru, S. ^{[6
]}

Gettinger, S. ^{[1
]}

Melnick, M. A. ^{[7
]}

Miao, J. ^{[2
]}

Moon, J. ^{[2
]}

Kelly, K. ^{[8
]}

Gandaram, D. ^{[9
]}

机构：

[1] Yale Univ, Sch Med, New Haven, CT USA

[2] Fred Hutchinson Canc Res Ctr, Swog Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[3] Duke Univ, Durham, NC USA

[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[5] Kaiser Permanente, Bellflower, CA USA

[6] Kaiser Permanente, Portland, OR USA

[7] Yale Sch Med, New Haven, CT USA

[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[9] Univ Calif Davis, Ctr Comprehens Canc, Div Hem Oncol, Sacramento, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

NSCLC; EGFR;

D O I：

10.1016/j.jtho.2018.08.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA10.04

引用

页码：S343 / S344

页数：2

共 50 条

[1] Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab
Mack, P.
Miao, J.
Banks, K.
Burich, R.
Politi, K.
Raymond, V.
Dix, D.
Lanman, R.
Moon, J.
Melnick, M. A.
Truini, A.
Redman, M.
Goldberg, S.
Gandara, D. R.
Kelly, K.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2219 - S2219
[2] Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
Goldberg, Sarah B.
Redman, Mary W.
Lilenbaum, Rogerio
Politi, Katerina
Stinchcombe, Thomas E.
Horn, Leora
Chen, Everett H.
Mashru, Sandeep H.
Gettinger, Scott N.
Melnick, Mary Ann
Herbst, Roy S.
Baumgart, Megan A.
Miao, Jieling
Moon, James
Kelly, Karen
Gandara, David R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
[3] Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Kim, Youjin
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
Sun, Jong-Mu
[J]. CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 502 - 509
[4] Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG 51403
Goldberg, Sarah
Moon, James
Lilenbaum, Rogerio
Politi, Katerina
Melnick, Mary Ann
Stinchcombe, Thomas
Horn, Leora
Chen, Everett
Miao, Jieling
Redman, Mary
Kelly, Karen
Gandara, David R.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1220 - S1221
[5] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
Gomes, Jessica Ribeiro
Cruz, Marcelo Rocha S.
[J]. ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
[6] Efficacy and safety of immunotherapy in EGFR-mutant advanced non-small cell lung cancer: A retrospective study
Tu, Tingting
Li, Yang
Liu, Ying
Jiang, Lifeng
[J]. ASIAN JOURNAL OF SURGERY, 2023, 46 (08) : 3275 - 3277
[7] The combined effect of afatinib and metformin on glycolytic regulation in EGFR-mutant non-small cell lung cancer
Barrios-Bernal, Pedro
Hernandez-Pedro, Norma Yanet
Soca-Chafre, Giovanny
Orozco-Morales, Mario
Arrieta, Oscar
[J]. CANCER RESEARCH, 2017, 77
[8] Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
Wen, Lei
Zhen, Junjie
Shan, Changguo
Lai, Mingyao
Hong, Weiping
Wang, Hui
Ye, Mingting
Yang, Yanying
Li, Shaoqun
Zhou, Zhaoming
Zhou, Jiangfen
Hu, Qingjun
Li, Juan
Tian, Xuwei
Chen, Longhua
Cai, Linbo
Xie, Zhanhong
Zhou, Cheng
[J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
[9] Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
Lei Wen
Junjie Zhen
Changguo Shan
Mingyao Lai
Weiping Hong
Hui Wang
Mingting Ye
Yanying Yang
Shaoqun Li
Zhaoming Zhou
Jiangfen Zhou
Qingjun Hu
Juan Li
Xuwei Tian
Longhua Chen
Linbo Cai
Zhanhong Xie
Cheng Zhou
[J]. European Journal of Medical Research, 28
[10] Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Dongliang Bian
Liangdong Sun
Junjie Hu
Liang Duan
Haoran Xia
Xinsheng Zhu
Fenghuan Sun
Lele Zhang
Huansha Yu
Yicheng Xiong
Zhida Huang
Deping Zhao
Nan Song
Jie Yang
Xiao Bao
Wei Wu
Jie Huang
Wenxin He
Yuming Zhu
Gening Jiang
Peng Zhang
[J]. Nature Communications, 14

← 1 2 3 4 5 →